Vistagen Therapeutics Reports Positive Exploratory Efficacy Data for Fasedienol

What Happened

• Vistagen Therapeutics, Inc. filed a Form 8-K on September 24, 2026 (Item 8.01) to announce a press release summarizing positive exploratory efficacy data presented at Psych Congress 2026. The data—reported in a conference poster and attached as Exhibit 99.1—showed a potential efficacy signal for fasedienol nasal spray in two separate double-blind, placebo-controlled public speaking challenge studies. The studies involved participants with very severe social anxiety disorder as defined by the Liebowitz Social Anxiety Scale (LSAS). Fasedienol is the company’s rapid-onset Phase 3 product candidate.

Key Details

• Filing date: September 24, 2026; press release attached to the 8-K as Exhibit 99.1.
• Data source: Poster presented at Psych Congress 2026 summarizing two double‑blind, placebo‑controlled public speaking challenge studies.
• Patient population: Participants with "very severe" social anxiety disorder per LSAS.
• Product stage: Fasedienol nasal spray is described as a rapid‑onset Phase 3 candidate.

Why It Matters

• The company is reporting an exploratory efficacy signal in controlled human challenge studies, which investors typically view as supportive early evidence for a drug’s mechanism and potential clinical benefit.
• These results relate directly to Vistagen’s ongoing Phase 3 development program for fasedienol; the announcement may inform how investors and analysts assess clinical progress.
• The filing is a disclosure of a press release and conference presentation; it does not provide definitive Phase 3 efficacy or regulatory outcomes.